3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase 2
1
Status
Terminated
1
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
3
Study Type
Interventional
3
Sponsor
Cancer Type
Breast
2
Thoracic
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Ovarian Neoplasms
3
Neoplasm Metastasis
3
Breast Neoplasms
3
Triple Negative Breast Neoplasms
2
Neoplasms
2
Multiple Myeloma
2
Melanoma
2
Fallopian Tube Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Thyroid Neoplasms
1
Prostatic Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Polycystic Ovary Syndrome
1
Peritoneal Neoplasms
1
Pancreatic Ductal Adenocarcinoma
1
Pain
1
Monoclonal Gammopathy of Undetermined Significance
1
Magnetic Resonance Imaging
1
Lymphoma, Follicular
1
Lung Neoplasms
1
Limited Stage Small Cell Lung Cancer
1
Kidney Neoplasms
1
Hypothyroidism
1
Hyperphagia
1
Hepatic Encephalopathy
1
Hematologic Neoplasms
1
Head and Neck Neoplasms
1
Goiter
1
Interventions
pembrolizumab
156
Gemcitabine
139
Capecitabine
121
Paclitaxel
119
Fluorouracil
116
Oxaliplatin
110
Bevacizumab
104
Nivolumab
97
Leucovorin
97
Docetaxel
93
Cisplatin
90
Irinotecan
88
Carboplatin
85
Radiosurgery
83
Cyclophosphamide
71
Cetuximab
70
Magnetic Resonance Spectroscopy
68
Trastuzumab
56
Specimen Handling
56
Biopsy
56
Radiotherapy
55
Ipilimumab
52
Everolimus
48
Pemetrexed
46
Drug Therapy
45
Albumin-Bound Paclitaxel
44
130-nm albumin-bound paclitaxel
43
Doxorubicin
41
Fulvestrant
38
aldesleukin
37
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Interventional
×
Neoplasm Metastasis
×
Glucose
×
Clear all
NCT04895358
2026-03-11
KEYNOTE-B49
Merck Sharp & Dohme LLC
Phase 3
Active not recruiting
340 enrolled
NCT04799249
2024-08-01
PRESERVE 2
G1 Therapeutics, Inc.
Phase 3
Completed
194 enrolled
NCT04863248
2023-04-14
PRESERVE 4
G1 Therapeutics, Inc.
Phase 2
Terminated
10 enrolled
14 charts